Abstract 11908: Organizational Structure, Resources, and Educational Initiatives in Cardiac Intensive Care Units: A National Cross-sectional Survey on Behalf of the American Heart Association Acute Cardiac Care Committee
Introduction: The acuity and medical complexity of patients admitted to cardiac intensive care units (CICUs) is increasing; yet, little is known about contemporary CICU organizational structures, staffing, resources, and educational activities in the United States
Methods: A cross-sectional, 16-question web-based survey was distributed electronically (October 2015) to AHA Mission: Lifeline coordinators at 542 registered hospitals with a request for completion by the CICU director or unit manager. Non-responders were contacted by email and phone.
Results: A total of 138 hospitals (25.5% response rate) had completed the survey by May 1, 2016 (17.4% academic, 20.3% tertiary non-academic, and 62.3% community hospitals). Most CICUs were open units (76.8%) with multiple simultaneous responsible attending physicians. The Figure shows variation in CICU patient populations, organizational structure, medical leadership and role of intensivists. Overall, 61% of centers participated in clinical training of housestaff and/or advanced practice providers, while only 8.5% of centers had a dedicated Cardiac Critical Care subspecialty training program. 12.3% of all CICUs had the organizational structure and on-site resources to be classified as a Level 1 CICU by 2012 American Heart Association Scientific Statement on CICU medical staffing and training models.
Conclusions: Among US hospitals, there was substantial variability in CICU organizational structure, practice, and educational activities. Approximately 1 in 10 CCUs had on-site resources necessary matching a Level 1 CICU classification. These data inform the current CICU landscape and may help to identify potential areas for organizational improvement and resource allocation.
Author Disclosures: C.B. Fordyce: None. Z. Wegermann: None. C.B. Granger: Research Grant; Modest; Armetheon, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, FDA, Glaxo SmithKline, Janssen Pharmaceuticals, The Medicines Company, Medtronic Foundation, Novartis, Pfizer, Sanofi-Aventis, Takeda, Bayer. Consultant/Advisory Board; Modest; Astra Zeneca, Bayer, Eli Lilly, Daiichi Sankyo, Gilead, Glaxo SmithKline, Hoffman-LaRoche, Janssen Pharmaceuticals, The Medicines Company, Medtronic, NIH, Novartis, Sanofi-Aventis, Takeda. Consultant/Advisory Board; Significant; Boehringer Ingelheim, Bristol Myers Squibb, Pfizer. A. Stebbins: None. D.A. Morrow: None. T.D. Henry: None. I.C. Gilchrist: None. J.N. Katz: None. M.G. Cohen: Speakers Bureau; Modest; Terumo Medical, Medtronic. Honoraria; Modest; Medtronic, Abiomed, Merit Medical.. Consultant/Advisory Board; Modest; The Medicines Company. L.K. Newby: Research Grant; Modest; Bristol Myers Squibb, Glaxo SmithKline, Verily, MURDOCK Study. Consultant/Advisory Board; Modest; American Association for Clinical Chemistry, American College of Cardiology, American College of Physicians, AstraZeneca, BASF, CAMC Health Education & Research Institute, CardioDx, Inc., Center for Human Genetics, Duke-NUS, DemeRx, JAHA, Korean Society of Cardiology, Medscape, LLC/The Heart.org, Merck & Co., Metanomics, Philips, Society of CV Patient Care. Consultant/Advisory Board; Significant; American Heart Association, Roche Diagnostic Corp.. S. Van Diepen: None.
- © 2016 by American Heart Association, Inc.